Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Price:
3.89 CNY
-1.27%
Market Closed
Updated:
May 18, 2024
P/OCF
Price to OCF
Price to OCF
9.4
Current
19.6
Median
17.4
Industry
Lower
than median
Lower
than industry value
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
P/OCF
=9.4
Market Cap
/
7.5B
Operating Cash Flow
791m
All Countries
| Market Cap | P/OCF | ||||
|---|---|---|---|---|---|
| CN |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
|
7.5B CNY | 9.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 199.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 43.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 16 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 22.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 24.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 14.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 18.6 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A
You don't have any saved screeners yet
